Because the therapeutic applications of stem cell exosomes are expanding, innovation within the market is also accelerating. New trends have emerged, including the use of stem cell exosomes as diagnostic tools and cell-free therapeutics. Additionally, numerous life science companies are offering tools and reagents to support exosome research.
Similarly, techniques for large-scale clinical-grade manufacture of stem cell exosomes is becoming a focal point within the industry, as highlighted by a recent partnership between RoosterBio and Exopharm, as well as Lonza’s intentions to enter the market through it recent acquisitions of HansaBioMed Life Sciences and investment into Exosomics made in May 2017.
Exosome-related technologies and applications have been developing rapidly over the past few years and substantial growth is expected for the market, as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine.[1] While exosomes derived from multiple stem cell types are now being explored, it is clear the mesenchymal stem cell (MSC) derived exosomes are best represented both within the scientific literature and within global patent activity.
On a broader scale, cancer derived exosomes are known to influence the invasive potential of both proximal and distal cells by regulating immunity, angiogenesis and metastasis, making them a potentially valuable source of biomarkers for use in cancer detection, diagnosis and therapy selection.[2]
On the venture capital front, there has also been a great deal of market activity, including funding rounds by Exosome Diagnostics in which the company raised nearly $80 million its Series A and Series B rounds.[3] More recently, on July 24, 2017, Exosome Diagnostics closed its $30 million Series C financing.[4]
Additionally, Codiak Biosciences was launched in late 2016 when the MD Anderson Cancer Center joined two venture capital firms and co-founder Dr. Eric Lander to launch the company with more than $80 million in series A and B financing. In May 2017, ExCoBio Inc. raised US $11 million in a Series A funding round.
Finally, Australian biotech company VivaZome Therapeutics was awarded a grant of $2.18M in December 2017 to support the project: Enabling Exosome Therapy: Developing an Advanced Manufacturing Process. It received the funds under the Australian government’s Advanced Manufacturing Scheme.
As a result of rapid technological advancement and increasing investment flowing into the sector, BioInformant has released a global strategic report that explores the growing demand for exosome therapeutics, diagnostics, research tools, cosmeceuticals, and manufacturing processes.
To learn more, view the “Market for Stem Cell Exosomes.”
Footnotes
[1] Marketwire. (2017). Avalon GloboCare Acquires Leading Beijing Exosome Technology Company. [online] Available at: http://www.marketwired.com/press-release/avalon-globocare-acquires-leading-beijing-exosome-technology-company-otcqb-avco-2238802.htm [Accessed 17 Nov. 2017].
[2] Soung, Y., Ford, S., Zhang, V. and Chung, J. (2017). Exosomes in Cancer Diagnostics.
|[3] Exosomedx.com. (2017). Investors | Exosome Diagnostics. [online] Available at: http://www.exosomedx.com/investors [Accessed 28 Aug. 2017].
[4] Exosome Diagnostics Completes $30 Million Series C Financing. [online] GlobeNewswire News Room. Available at: https://globenewswire.com/news-release/2017/07/24/1056075/0/en/Exosome-Diagnostics-Completes-30-Million-Series-C-Financing.html [Accessed 31 Aug. 2017].